The development of the anti-HER2 monoclonal antibody trastuzumab marked a major breakthrough in the treatment of HER2 + breast cancers [4], but progression-free survival (PFS) was often measured in months [5]. This evidence concerns the gene ERBB2 and breast carcinoma.